Article
Immunology
Shuang Fan, Tian-Zhong Pan, Li-Ping Dou, Yan-Min Zhao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The study aimed to assess the efficacy of preemptive interferon-alpha (IFN-alpha) treatment in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a real-world setting. The results showed that preemptive IFN-alpha treatment can eliminate measurable residual disease (MRD) in AML patients and improve leukemia-free survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Carmine Liberatore, Mauro Di Ianni
Summary: The management of relapsed acute myeloid leukemia (AML) post allogeneic hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Hypomethylating agents (HMAs) have become the standard therapeutic approach due to favorable tolerability and their ability to be combined with other anti-leukemic agents. The addition of donor lymphocytes infusions (DLI) generally leads to improved outcomes, while the introduction of novel targeted drugs offers new possibilities in salvage regimens.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Enrico Maffini, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafe, Mario Arpinati, Francesca Bonifazi
Summary: Disease relapse post hematopoietic cell transplantation remains a major challenge, with novel cellular and biological therapies showing promise in treating acute leukemia relapse. Understanding the pathobiology of leukemia relapse is crucial for developing new therapeutic strategies, including targeted therapies and novel drug combinations.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Hee-Je Kim, Yonggoo Kim, Dain Kang, Hoon Seok Kim, Jong-Mi Lee, Myungshin Kim, Byung-Sik Cho
Summary: Limited studies on NGS-MRD in AML patients after allo-HSCT prompted this research, which found a significant association between persistent mutations detected pre-HSCT and 1 month post-HSCT with post-transplant relapse and overall survival. Detectable mutations in genes associated with clonal hematopoiesis were also predictive of post-transplant relapse. Serial NGS-MRD monitoring was shown to compensate for the limitations of the initial assay performance.
BLOOD CANCER JOURNAL
(2021)
Review
Oncology
Desiree Kunadt, Friedrich Stoelzel
Summary: The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has been increasing due to advances in transplant technology, supportive care, transplant safety, and donor availability. Acute myeloid leukemia (AML) is the most common indication for alloHCT, but disease relapse remains a major challenge. Maintaining a strong graft-versus-leukemia (GvL) effect is crucial for patient prognosis and long-term survival.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Immunology
Yimei Feng, Ting Chen, Yun Zhang, Han Yao, Ping Wang, Lu Wang, Kaniel Cassady, Zhongmin Zou, Yuqing Liu, Lu Zhao, Lei Gao, Xi Zhang, Peiyan Kong
Summary: This study examines the efficacy and tolerability of maintenance therapy with azacytidine (AZA) plus low-dose lenalidomide (LEN) to prevent relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) patients. The results show that this treatment regimen plays a significant role in preventing relapse without significantly increasing the risk of complications post-transplantation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Infectious Diseases
Alexa A. Ciarolla, Norman Lapin, Dustin Williams, Rajiv Chopra, David E. Greenberg
Summary: Prosthetic joint infection (PJI) is a challenging clinical problem primarily due to the presence of biofilm, which makes infection eradication difficult. This review explores non-pharmacological methods, such as heat, light, sound, and electromagnetic energy, for preventing and treating biofilm in the body and their potential use in PJI treatment. Although these methods are still being studied, they offer a potential way to reduce the morbidity and financial burden associated with current PJI treatment methods. This review provides an assessment of each method, their progress, and discusses future challenges for implementing them in a clinical setting.
Review
Oncology
Giulia Ciotti, Giovanni Marconi, Giovanni Martinelli
Summary: Allogeneic stem cell transplantation is a preferred treatment for acute myeloid leukemia, but relapse rates are high. Hypomethylating agents (HMAs) show promise as a backbone for combination therapies, particularly in combination with donor lymphocyte infusion (DLI). Other combination strategies with lenalidomide and tyrosine kinase inhibitors have shown competitive response rates. However, gemtuzumab ozogamicin and immune checkpoint inhibitors have shown less promising results. Furthermore, investigation into histone deacetylase inhibitors and isocitrate dehydrogenase 1 and 2 (IDH1/2) inhibitors as combination strategies is needed.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Natalie Kohler, Dietrich Alexander Ruess, Rebecca Kesselring, Robert Zeiser
Summary: Immune checkpoint molecules play a crucial role in relapse and treatment after allo-HCT by inhibiting the graft-versus-leukemia effect, allowing tumor cells to escape. The activation of inhibitory receptors on T cell surfaces by immune checkpoint molecules facilitates immune escape. Research shows that immune checkpoint blockade holds potential value in improving the immunotherapeutic effect of relapse after allo-HCT.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Biophysics
Siba El Hussein, Courtney D. DiNardo, Koichi Takahashi, Joseph D. Khoury, Hong Fang, Ken Furudate, Kirill A. Lyapichev, Sofia Garces, Rashmi Kanagal-Shamanna, Chi Young Ok, Keyur P. Patel, Mark J. Routbort, Farhad Ravandi, L. Jeffrey Medeiros, Sa A. Wang, Sanam Loghavi
Summary: WT1 mutations contribute to relapse in NPM1 mutated AML, especially in the setting of HSCT.
BONE MARROW TRANSPLANTATION
(2022)
Review
Oncology
Iman Abou Dalle, Ali Atoui, Ali Bazarbachi
Summary: Relapsed acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (allo-HCT) is a challenging event, and the current treatment landscape is still facing difficulties. Recent research has allowed the development of new strategies that can improve remission rates and prolong survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Miriam Mozaffari Jovein, Gabriele Ihorst, Jesus Duque-Afonso, Ralph Waesch, Hartmut Bertz, Claudia Wehr, Justus Duyster, Robert Zeiser, Juergen Finke, Florian Scherer
Summary: This study evaluated the long-term outcomes of 220 AML patients after primary induction failure (PIF) who underwent allogeneic hematopoietic stem cell transplantation (HCT). The results showed that immediate allogeneic HCT after PIF provides long-term survival and cure in a high-risk population.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Ruiqi Li, Ziwei Wang, Yuesheng Zhang, Mengqiao Guo, Xiong Ni, Jie Chen, Li Chen, Lei Gao, Shenglan Gong, Gusheng Tang, Jianmin Yang, Jianmin Wang
Summary: This study analyzed 34 AML patients who relapsed after allo-HSCT and found that cytogenetic evolution (CGE) had a significant impact on the prognosis, with more complex cytogenetic characteristics in the CGE group. The 6-month post-relapse overall survival was significantly lower in the CGE group. Other factors such as the occurrence of chronic graft-versus-host disease and conditioning regimen were also associated with the prognosis.
ANNALS OF HEMATOLOGY
(2023)
